A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).
Tumors or cancer of the SKIN.
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
The term applied to a group of relatively uncommon inflammatory, maculopapular, scaly eruptions of unknown etiology and resistant to conventional treatment. Eruptions are both psoriatic and lichenoid in appearance, but the diseases are distinct from psoriasis, lichen planus, or other recognized dermatoses. Proposed nomenclature divides parapsoriasis into two distinct subgroups, PITYRIASIS LICHENOIDES and parapsoriasis en plaques (small- and large-plaque parapsoriasis).
Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA).
A disease of the pilosebaceous unit, presenting clinically as grouped follicular papules or plaques with associated hair loss. It is caused by mucinous infiltration of tissues, and usually involving the scalp, face, and neck. It may be primary (idiopathic) or secondary to mycosis fungoides or reticulosis.
The use of ultraviolet electromagnetic radiation in the treatment of disease, usually of the skin. This is the part of the sun's spectrum that causes sunburn and tanning. Ultraviolet A, used in PUVA, is closer to visible light and less damaging than Ultraviolet B, which is ionizing.
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
A condition caused by a deficiency or a loss of melanin pigmentation in the epidermis, also known as hypomelanosis. Hypopigmentation can be localized or generalized, and may result from genetic defects, trauma, inflammation, or infections.
Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
Clinically benign, histologically malignant, recurrent cutaneous T-cell lymphoproliferative disorder characterized by an infiltration of large atypical cells surrounded by inflammatory cells. The atypical cells resemble REED-STERNBERG CELLS of HODGKIN DISEASE or the malignant cells of CUTANEOUS T-CELL LYMPHOMA. In some cases, lymphomatoid papulosis progresses to lymphomatous conditions including MYCOSIS FUNGOIDES; HODGKIN DISEASE; CUTANEOUS T-CELL LYMPHOMA; or ANAPLASTIC LARGE-CELL LYMPHOMA.
'Skin diseases' is a broad term for various conditions affecting the skin, including inflammatory disorders, infections, benign and malignant tumors, congenital abnormalities, and degenerative diseases, which can cause symptoms such as rashes, discoloration, eruptions, lesions, itching, or pain.
A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.
The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed)
Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.
Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Material, usually gauze or absorbent cotton, used to cover and protect wounds, to seal them from contact with air or bacteria. (From Dorland, 27th ed)
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A general term for various neoplastic diseases of the lymphoid tissue.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.

Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. (1/348)

Granzyme B (GrB) and T-cell-restricted intracellular antigen (TIA-1) are cytotoxic proteins that are specifically expressed by cytotoxic CD4 or CD8 positive T cells and natural killer cells. Recent studies demonstrated frequent expression of GrB and TIA-1 by neoplastic cells in primary cutaneous CD30(+) large T-cell lymphomas and lymphomatoid papulosis but not in CD30(-) large T-cell lymphomas. In the present study, 74 biopsies from 54 patients with mycosis fungoides (MF) were investigated for the expression of GrB and TIA-1 using immunohistochemistry on paraffin sections. Staining of more than 10% of the neoplastic T cells for GrB or TIA-1 was considered positive. All but two follow-up biopsies had been obtained from patients without extracutaneous disease at the time of biopsy. Expression of TIA-1 and GrB was found in 33 (45%) and 14 (19%) of 74 MF biopsies, respectively. Comparison of biopsies from T3NoMo-stage MF (n = 27) and T2NoMo-stage MF (n = 45) showed increased expression of TIA-1 (55 versus 37%) and GrB (33 versus 9%) in T3NoMo-stage MF. Evaluation of multiple sequential biopsies from successive stages of MF also revealed an increase in the GrB/TIA-1 expression with tumor progression in five of eight cases. A clearcut relation between the expression of TIA-1 and/or GrB and the type of skin lesion biopsied was found. Considering all 74 biopsies, expression of TIA-1 and GrB was found in 18 of 50 (35%) and 5 of 50 (10%) patches or plaques, 9 of 16 (55%) and 3 of 16 (20%) tumors without blastic transformation, and 6 of 8 (75%) and 6 of 8 (75%) tumors with blastic transformation (defined as >50% blast cells). Correlation between GrB/TIA-1 expression in first diagnostic biopsies from patches or plaques from 40 patients with T2NoMo-stage MF and clinical follow-up data did not reveal differences in clinical behavior and survival between patients with (n = 14) or without (n = 26) expression of cytotoxic proteins, indicating that MF expressing cytotoxic proteins should not be considered as a separate group.  (+info)

Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary syndrome. The French Study Group on Cutaneous Lymphomas. (2/348)

Prognostic studies of primary cutaneous lymphomas (PCL) other than mycosis fungoides (MF) and the Sezary syndrome (SS; non-MF/SS PCL) have been mainly performed on subgroups or on small numbers of patients by using univariate analyses. Our aim was to identify independent prognostic factors in a large series of patients with non-MF/SS PCL. We evaluated 158 patients who were registered in the French Study Group on Cutaneous Lymphomas database from January 1, 1986 to March 1, 1997. Variables analyzed for prognostic value were: age; sex; type of clinical lesions; maximum diameter, location, and number of skin lesions; cutaneous distribution (ie, local, regional, or generalized); prognostic group according to the European Organization for Research and Treatment of Cancer (EORTC) classification for PCL; B- or T-cell phenotype; serum lactate dehydrogenase (LDH) level; and B symptoms. Univariate and multivariate analyses were performed using a model of relative survival. Forty-nine patients (31%) died. The median relative survival time was 81 months. In univariate analysis, EORTC prognostic group, serum LDH level, B symptoms, and variables related to tumor extension (ie, distribution, maximum diameter, and number of skin lesions) were significantly associated with survival. When these variables were considered together in a multivariate analysis, EORTC prognostic group and distribution of skin lesions remained statistically significant, independent prognostic factors. This study confirms the good predictive value of the EORTC classification for PCL and shows that the distribution of skin lesions at initial evaluation is an important prognostic indicator.  (+info)

Ophthalmic abnormalities in patients with cutaneous T-cell lymphoma. (3/348)

PURPOSE: To determine the frequency of ophthalmic abnormalities in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and T-cell lymphoma involving the skin and to describe the clinical course of the disease with selected examples. METHODS: A computerized diagnostic retrieval system was used to identify all patients with T-cell lymphoma involving the skin who were examined at the Mayo Clinic (Rochester, Minnesota) between January 1, 1976 and December 31, 1990. The medical records of affected patients were reviewed. RESULTS: During the 15-year interval from 1976 through 1990, cutaneous T-cell lymphoma was diagnosed in 2,155 patients. Of these 2,155 patients, 42 (1.95%; 26 male and 16 female) had at least 1 ophthalmic abnormality attributable to the disease. The diagnoses in these 42 patients were mycosis fungoides in 19, clinical variants of T-cell lymphoma of the skin (most commonly, peripheral T-cell lymphoma) in 11, and Sezary syndrome in 12. Cicatricial eyelid ectropion was the most common finding, affecting 17 (40.4%) of the 42 patients. Thirty-seven patients had findings that, although probably not a direct consequence of cutaneous T-cell lymphoma, have been cataloged in previous studies. CONCLUSION: Although ophthalmic abnormalities in patients with cutaneous T-cell lymphoma are relatively uncommon, the manifestations of the disease are diverse and frequently difficult to treat.  (+info)

Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. (4/348)

OBJECTIVES: Patterns of mycosis fungoides incidence and associated mortality in the United States were evaluated. METHODS: Data were taken from the Surveillance, Epidemiology, and End Results cancer registry program and the National Center for Health Statistics. RESULTS: The incidence rate from 1973 through 1992 was 0.36/10(5) person-years. The age-adjusted incidence rate ratio of Blacks to Whites was 1.7; that of Asians to Whites was 0.6. There was no evidence of increasing incidence rates during the period 1983 through 1992. Mortality rates declined steadily from 1979 to 1991 and were less heterogeneous geographically than incidence rates. Mortality rate patterns with age, sex, and race were similar to the corresponding incidence patterns. CONCLUSIONS: The incidence rate of mycosis fungoides has stabilized and the mortality rate has declined. For unknown reasons, the disorder varies greatly among demographic and geographic subgroups.  (+info)

O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. (5/348)

Mycosis fungoides is a low-grade cutaneous T-cell lymphoma. Early treatment often involves the use of topical chemotherapy such as mechlorethamine or carmustine although single-agent oral chemotherapy with alkylators is common for advanced disease. Recently, in a Phase I study of the new alkylating agent temozolomide, two mycosis fungoides patients experienced a complete response. The mechanism of resistance to alkylating drugs such as temozolomide is thought to be due to the presence in tumor cells of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT). The protein mediates a reaction with the O6-position of guanine in DNA, removing the lesion and leaving guanine intact. We, therefore, examined the levels of AGT in CD4+ T lymphocytes obtained by negative antibody selection from the blood of noncancerous individuals and mycosis fungoides patients, and in paraffin-embedded sections from mycosis fungoides patch, plaque, or tumor lesions and cells from involved lymph nodes. AGT protein levels were measured by quantitative immunofluorescence microscopy using a monoclonal antibody against human AGT. Using this approach, the mean level of our positive control (AGT-expressing cells) was 84,807 molecules/nucleus; values below 5,000 molecules/nucleus are considered very low. The mean AGT level in CD4+ T lymphocytes from noncancerous and cancerous individuals was 18,618 (n = 12) and 8,593 (n = 5), respectively. The mean fraction of outliers in circulating CD4+ T lymphocytes from mycosis fungoides patients was statistically significantly lower than T cells in lymph nodes. AGT molecules/nucleus from lymph node biopsies from 8 of 10 patients showed low (< 10,000 molecules/nucleus) or undetectable levels (n = 5) of AGT. The mean AGT level from samples of mycosis fungoides patch/plaque and tumor was also low at 221 (n = 4) and 2,363 (n = 6), respectively. Surprisingly, Hut78, a mycosis fungoides T-cell lymphoma cell line, was positive for AGT activity (median: 77,700 molecules/nucleus), and Hut102--another mycosis fungoides cell line--was low (median: 5,990 molecules/nucleus). Because AGT is a primary means of cell resistance to alkylating agents, the low level of AGT in neoplastic T lymphocytes from patients with mycosis fungoides suggests that treatment with alkylating agents producing O6-alkylguanine adducts, such as carmustine or temozolomide, may produce improved clinical outcomes.  (+info)

Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. (6/348)

BACKGROUND AND OBJECTIVE: The early stages of mycosis fungoides (MF) can be treated but not cured by photochemotherapy (PUVA) alone; some recent studies of the effect of a combination of human interferon-alpha (IFN(alpha)) and PUVA reported a high degree of response. The aim of our study was to evaluate the activity of a low dose of IFN-alpha2b combined with PUVA. DESIGN AND METHODS: Twenty-five patients were included: 16 men and 9 women aged between 23-80 years; 19 patients ahd stage I and 6 stage II disease. In the induction phase, the dose of IFNalpha was gradually raised over 6-8 weeks to the target dose of 18 MU/week; in the maintenance phase, the combination with PUVA allowed IFNalpha to be reduced to a maximum dose of 6 MU/week; in this way the cumulative administration of IFNalpha and PUVA was considerably lower than in similar combination protocols. Treatment success was analyzed in terms of freedom from treatment failure (FFTF). RESULTS: After the induction phase 9/25 patients (36%) achieved complete remission (CR) and 15/25 (56%) achieved partial remission (PR). One to five months from the beginning of the maintenance phase, a CR was recorded in 19/25 patients (76%) and a PR in 5/25 patients (20%) accounting for an overall response rate of 96%. The median of FFTF was not reached; probability of FFTF was 82% at 12 months and 62% at 24 months. Disease free survival projected to 48 months was 75%. INTERPRETATION AND CONCLUSIONS: Even with low doses of IFNalpha plus PUVA it is possible to achieve excellent clinical responses,many of which are long-lasting, in patients with early MF.  (+info)

A novel Epstein-Barr virus-like virus, HV(MNE), in a Macaca nemestrina with mycosis fungoides. (7/348)

Epstein-Barr virus (EBV) infection of humans has been associated with the development of lymphoid malignancies mainly of B-cell lineage, although occasionally T-cell lymphomas have been reported. We describe here the characterization of a novel EBV-like virus (HV(MNE)) isolated from a simian T-cell lymphotropic virus type I/II (STLV-I/II) seronegative pigtailed macaque (Macaca nemestrina) with a cutaneous T-cell lymphoma. Immunohistochemistry studies on the skin lesions demonstrated that the infiltrating cells were of the CD3(+)/CD8(+) phenotype. Two primary transformed CD8(+) T-cell lines were obtained from cultures of peripheral blood mononuclear cells (PBMC) and skin, and, with time, both cell lines became interleukin-2-independent and acquired the constitutive activation of STAT proteins. Polymerase chain reaction analysis of the DNA from the cell lines and tissues from the lymphomatous animal demonstrated the presence of a 536-bp DNA fragment that was 90% identical to EBV polymerase gene sequences, whereas the same DNA was consistently negative for STLV-I/II sequences. Electron microscopy performed on both cell lines, after sodium butyrate treatment, showed the presence of a herpes-like virus that was designated HV(MNE) according to the existing nomenclature. In situ hybridization studies using EBV Epstein-Barr viral-encoded RNA probes showed viral RNA expression in both CD8(+) T-cell lines as well as in the infiltrating CD8(+) T cells of skin-tissue biopsies. Phylogenetic analysis of a 465-bp fragment from the polymerase gene of HV(MNE) placed this virus within the Lymphocryptovirus genus and demonstrated that HV(MNE) is a distinct virus, clearly related to human EBV and other EBV-like herpesviruses found in nonhuman primates.  (+info)

Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. (8/348)

Interleukin-16 is a soluble ligand to the CD4 molecule with chemotactic properties for CD4+ cells and a competence growth factor for CD4+ T cells, upregulating HLA-DR and the interleukin-2 receptor CD25. There is also evidence for a synergistic effect of interleukin-16 and interleukin-2 on the activation of CD4+ T cells. The infiltrate in mycosis fungoides, the most common cutaneous T cell lymphoma, is typically CD4+. We tested the possibility that interleukin-16 is involved in the formation and progression of these lesions. By reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated. By competitive reverse transcription-polymerase chain reaction, interleukin-16 mRNA expression increased with disease stage. Secreted interleukin-16 was detected by enzyme-linked immunosorbent assay in both Th1- and Th2-like T cell clones (as characterized by their production of interferon-gamma and interleukin-4) grown from lesional dermis and epidermis. By immunohistochemistry and in situ hybridization, infiltrating lymphocytes were the main producers of interleukin-16 whereas keratinocytes and endothelial cells remained negative. Atypical cells with convoluted nuclei were also positive. In advanced mycosis fungoides stages, many blast-like cells were positive, but some larger blasts remained negative. Interleukin-16 expression correlated positively with the expression of interleukin-2 and its receptor CD25 in individual skin lesions. Interleukin-2 expression, however, was weak or absent in samples from uninvolved skin, healthy controls and lesional psoriasis. Given the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.  (+info)

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), a rare cancer that affects the skin's immune system. It is characterized by the infiltration of malignant CD4+ T-lymphocytes into the skin, leading to the formation of patches, plaques, and tumors. The disease typically progresses slowly over many years, often starting with scaly, itchy rashes that can be mistaken for eczema or psoriasis. As the disease advances, tumors may form, and the lymphoma may spread to other organs, such as the lymph nodes, lungs, or spleen. Mycosis fungoides is not contagious and cannot be spread from person to person. The exact cause of mycosis fungoides is unknown, but it is thought to result from a combination of genetic, environmental, and immune system factors.

Sezary Syndrome is a rare and aggressive form of cutaneous T-cell lymphoma (CTCL), a type of cancer that involves the skin's immune system. It is characterized by the presence of malignant T-lymphocytes, known as Sezary cells, in the blood, skin, and lymph nodes.

Sezary cells are typically found in large numbers in the peripheral blood, and they have a distinctive appearance with convoluted or "cerebriform" nuclei. These cells can infiltrate the skin, leading to erythroderma (a widespread redness and scaling of the skin), pruritus (severe itching), alopecia (hair loss), and lymphadenopathy (swelling of the lymph nodes).

Sezary Syndrome is often treatment-resistant, and its prognosis is generally poor. Treatment options may include chemotherapy, radiation therapy, photopheresis, immunotherapy, and stem cell transplantation.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Cutaneous T-cell lymphoma (CTCL) is a type of cancer that affects T-cells, a specific group of white blood cells called lymphocytes. These cells play a crucial role in the body's immune system and help protect against infection and disease. In CTCL, the T-cells become malignant and accumulate in the skin, leading to various skin symptoms and lesions.

CTCL is a subtype of non-Hodgkin lymphoma (NHL), which refers to a group of cancers that originate from lymphocytes. Within NHL, CTCL is categorized as a type of extranodal lymphoma since it primarily involves organs or tissues outside the lymphatic system, in this case, the skin.

The two most common subtypes of CTCL are mycosis fungoides and Sézary syndrome:

1. Mycosis fungoides (MF): This is the more prevalent form of CTCL, characterized by patches, plaques, or tumors on the skin. The lesions may be scaly, itchy, or change in size, shape, and color over time. MF usually progresses slowly, with early-stage disease often confined to the skin for several years before spreading to lymph nodes or other organs.
2. Sézary syndrome (SS): This is a more aggressive form of CTCL that involves not only the skin but also the blood and lymph nodes. SS is characterized by the presence of malignant T-cells, known as Sézary cells, in the peripheral blood. Patients with SS typically have generalized erythroderma (reddening and scaling of the entire body), pruritus (severe itching), lymphadenopathy (swollen lymph nodes), and alopecia (hair loss).

The diagnosis of CTCL usually involves a combination of clinical examination, skin biopsy, and immunophenotyping to identify the malignant T-cells. Treatment options depend on the stage and subtype of the disease and may include topical therapies, phototherapy, systemic medications, or targeted therapies.

Parapsoriasis is a term used to describe two uncommon, chronic, and relatively benign inflammatory skin conditions. These are small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP), also known as retiform or digitate dermatosis of Köbner.

Small plaque parapsoriasis is characterized by scaly, thin, pink to red patches or plaques, usually less than 3-5 cm in diameter. The lesions are often asymptomatic or mildly pruritic and can be found on the trunk and proximal extremities.

Large plaque parapsoriasis presents as larger, irregularly shaped, scaly patches or thin plaques, typically greater than 5 cm in diameter. The lesions are often asymptomatic but may occasionally be pruritic. LPP is considered a precursor to a rare cutaneous T-cell lymphoma called mycosis fungoides, especially when the lesions become thicker or more numerous over time.

It's important to note that these conditions can sometimes be challenging to diagnose and may require a skin biopsy for accurate diagnosis. Dermatologists and pathologists should carefully evaluate the clinical presentation, histopathological features, and any potential progression to ensure appropriate management.

PUVA therapy is a type of treatment that uses both medication and light to treat certain skin conditions, such as psoriasis, eczema, and cutaneous T-cell lymphoma. The name "PUVA" stands for Psoralen + UVA, which refers to the two main components of the therapy:

1. Psoralen: This is a medication that makes the skin more sensitive to light. It can be taken orally or applied directly to the skin in the form of a cream or bath.
2. UVA: This stands for Ultraviolet A, which is a type of light that is part of the natural sunlight spectrum. In PUVA therapy, the skin is exposed to a controlled dose of UVA light in a special booth or room.

When psoralen is introduced into the body, it absorbs into the skin and makes it more sensitive to UVA light. When the skin is then exposed to UVA light, it triggers a chemical reaction that slows down the growth of affected skin cells. This helps to reduce inflammation, scaling, and other symptoms associated with the skin condition being treated.

It's important to note that PUVA therapy can have side effects, including sunburn, itching, redness, and an increased risk of skin cancer over time. As such, it is typically used as a second-line treatment when other therapies have not been effective, and it is closely monitored by a healthcare professional to ensure its safe and effective use.

Follicular mucinosis is a cutaneous condition characterized by the accumulation of mucin in the hair follicles. Mucin is a complex sugar-protein substance that provides cushioning and lubrication in various tissues throughout the body. In follicular mucinosis, there is an overproduction of mucin within the hair follicles, leading to visible bumps or papules on the skin.

Follicular mucinosis can be classified into three types: primary, secondary, and variant. The primary type is further divided into two subcategories: classic and atypical. The classic form of primary follicular mucinosis typically affects middle-aged adults and presents with localized or generalized patches of skin that are scaly, itchy, and have a smooth, shiny appearance (known as "alopetic pseudopelade"). In contrast, the atypical form is often associated with lymphoma.

Secondary follicular mucinosis can occur in association with various inflammatory skin conditions, such as eczema, psoriasis, and discoid lupus erythematosus. The variant type of follicular mucinosis is a rare condition that primarily affects children and adolescents, presenting with localized areas of thickened, rough skin (known as "hyperkeratotic").

The exact cause of primary follicular mucinosis remains unclear, but it is thought to involve an abnormal immune response. Secondary follicular mucinosis, on the other hand, is a reactive process triggered by underlying inflammatory skin conditions. Treatment for follicular mucinosis depends on the type and severity of the condition, ranging from topical corticosteroids to systemic immunosuppressive therapy in more severe cases.

Ultraviolet (UV) therapy, also known as phototherapy, is a medical treatment that uses ultraviolet light to treat various skin conditions. The UV light can be delivered through natural sunlight or artificial sources, such as specialized lamps or lasers.

In medical settings, controlled doses of UV light are used to target specific areas of the skin. The most common type of UV therapy is narrowband UVB (NB-UVB) phototherapy, which uses a specific wavelength of UVB light to treat conditions such as psoriasis, eczema, vitiligo, and dermatitis.

The goal of UV therapy is to reduce inflammation, slow skin cell growth, and improve the overall appearance of the skin. It is important to note that while UV therapy can be effective in treating certain skin conditions, it also carries risks such as skin aging and an increased risk of skin cancer. Therefore, it should only be administered under the supervision of a qualified healthcare professional.

In medical terms, the skin is the largest organ of the human body. It consists of two main layers: the epidermis (outer layer) and dermis (inner layer), as well as accessory structures like hair follicles, sweat glands, and oil glands. The skin plays a crucial role in protecting us from external factors such as bacteria, viruses, and environmental hazards, while also regulating body temperature and enabling the sense of touch.

Acitretin is a synthetic form of retinoic acid, which is a type of vitamin A. It is used to treat severe psoriasis and other skin conditions. Acitretin works by slowing down the rapid growth of skin cells that cause the symptoms of psoriasis. It comes in the form of a capsule and is taken orally.

Common side effects of acitretin include dryness of the skin, lips, and mouth, itching, peeling, redness, or stickiness of the palms and soles, hair loss, and changes in nail growth. Less common but more serious side effects can include liver damage, increased levels of lipids in the blood, and birth defects if taken during pregnancy.

It is important to note that acitretin can cause birth defects, so women who are pregnant or planning to become pregnant should not take this medication. Additionally, because acitretin can remain in the body for a long time, it is recommended that women of childbearing age use effective contraception while taking this medication and for at least three years after stopping it.

Hypopigmentation is a medical term that refers to a condition where there is a decrease in the amount of pigment (melanin) in the skin, resulting in lighter patches or spots on the skin. This can occur due to various reasons such as skin injuries, certain skin disorders like vitiligo, fungal infections, burns, or as a side effect of some medical treatments like chemotherapy or radiation therapy. It is different from albinism, which is a genetic condition where the body is unable to produce melanin at all.

CD7 is a type of protein found on the surface of certain cells in the human body, including some immune cells like T-cells and natural killer cells. It is a type of antigen that can be recognized by other immune cells and their receptors, and it plays a role in the regulation of the immune response.

CD7 antigens are often used as targets for immunotherapy in certain types of cancer, as they are overexpressed on the surface of some cancer cells. For example, anti-CD7 monoclonal antibodies have been developed to target and kill CD7-positive cancer cells, or to deliver drugs or radiation directly to those cells.

It's important to note that while CD7 is a well-established target for immunotherapy in certain types of cancer, it is not a specific disease or condition itself. Rather, it is a molecular marker that can be used to identify and target certain types of cells in the body.

Lymphomatoid papulosis (LyP) is a rare, chronic skin disorder characterized by recurrent, self-healing papules and nodules. It is considered a low-grade T-cell lymphoma, but it is distinct from other cutaneous lymphomas due to its benign clinical course and lack of systemic involvement in most cases. The lesions typically undergo cycles of appearing, ulcerating, and then resolving over a period of several weeks to months, only to recur elsewhere on the body.

Histologically, LyP is characterized by an inflammatory infiltrate composed of small lymphocytes, histiocytes, eosinophils, and atypical large cells with Reed-Sternberg-like morphology. The condition is often associated with other lymphoproliferative disorders, such as mycosis fungoides or Hodgkin's lymphoma, and it is important to monitor patients closely for signs of progression to more aggressive lymphomas.

The exact cause of LyP remains unclear, but it is thought to involve an abnormal immune response and genetic factors. Treatment options include topical therapies, phototherapy, and systemic medications such as methotrexate or retinoids. However, the choice of treatment depends on the severity and extent of the disease, as well as the individual patient's needs and preferences.

Skin diseases, also known as dermatological conditions, refer to any medical condition that affects the skin, which is the largest organ of the human body. These diseases can affect the skin's function, appearance, or overall health. They can be caused by various factors, including genetics, infections, allergies, environmental factors, and aging.

Skin diseases can present in many different forms, such as rashes, blisters, sores, discolorations, growths, or changes in texture. Some common examples of skin diseases include acne, eczema, psoriasis, dermatitis, fungal infections, viral infections, bacterial infections, and skin cancer.

The symptoms and severity of skin diseases can vary widely depending on the specific condition and individual factors. Some skin diseases are mild and can be treated with over-the-counter medications or topical creams, while others may require more intensive treatments such as prescription medications, light therapy, or even surgery.

It is important to seek medical attention if you experience any unusual or persistent changes in your skin, as some skin diseases can be serious or indicative of other underlying health conditions. A dermatologist is a medical doctor who specializes in the diagnosis and treatment of skin diseases.

Vitiligo is a medical condition characterized by the loss of pigmentation in patches of skin, resulting in irregular white depigmented areas. It's caused by the destruction of melanocytes, the cells responsible for producing melanin, which gives our skin its color. The exact cause of vitiligo is not fully understood, but it's thought to be an autoimmune disorder where the immune system mistakenly attacks and destroys melanocytes. It can affect people of any age, gender, or ethnicity, although it may be more noticeable in people with darker skin tones. The progression of vitiligo is unpredictable and can vary from person to person. Treatment options include topical creams, light therapy, oral medications, and surgical procedures, but the effectiveness of these treatments varies depending on the individual case.

Methoxsalen is a medication that belongs to the class of drugs known as psoralens. It is primarily used in the treatment of skin conditions such as psoriasis and vitiligo.

Methoxsalen works by making the skin more sensitive to ultraviolet light A (UVA) after it is absorbed. This process helps to slow down the growth of affected skin cells, reducing the symptoms of the condition.

The medication is typically taken orally or applied topically to the affected area before UVA light therapy. It's important to note that methoxsalen can increase the risk of skin cancer and cataracts with long-term use, so it should only be used under the close supervision of a healthcare provider.

Exfoliative dermatitis is a severe form of widespread inflammation of the skin (dermatitis), characterized by widespread scaling and redness, leading to the shedding of large sheets of skin. It can be caused by various factors such as drug reactions, underlying medical conditions (like lymphoma or leukemia), or extensive eczema. Treatment typically involves identifying and removing the cause, along with supportive care, such as moisturizers and medications to control inflammation and itching. In severe cases, hospitalization may be necessary for close monitoring and management of fluid and electrolyte balance.

Gamma-chain T-cell antigen receptor gene rearrangement refers to the genetic process that occurs during the development of T-cells in the thymus. The T-cell antigen receptor (TCR) is a protein complex found on the surface of T-cells, which plays a critical role in adaptive immunity by recognizing and binding to specific peptide antigens presented in the context of major histocompatibility complex (MHC) molecules.

The TCR is composed of two types of polypeptide chains: alpha and beta chains or gamma and delta chains, which are encoded by separate genes. The gene rearrangement process involves the somatic recombination of variable (V), diversity (D), joining (J), and constant (C) gene segments to generate a diverse repertoire of TCRs capable of recognizing a wide range of antigens.

Gamma-chain TCR gene rearrangement specifically refers to the genetic rearrangement that occurs in the genes encoding the gamma chain of the TCR. This process involves the recombination of V, J, and C gene segments to form a functional gamma chain gene. The resulting gamma chain protein pairs with the delta chain to form the gamma-delta TCR, which is expressed on a subset of T-cells that have distinct functions in immune surveillance and defense against infections and cancer.

Abnormalities in gamma-chain TCR gene rearrangement can lead to the development of various immunodeficiency disorders or malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) or gamma-delta T-cell lymphomas.

Mechlorethamine is an antineoplastic agent, which means it is used to treat cancer. It is a type of alkylating agent, which is a class of drugs that work by interfering with the DNA of cancer cells, preventing them from dividing and growing. Mechlorethamine is used in the treatment of Hodgkin's lymphoma and non-Hodgkin's lymphoma, as well as some other types of cancer. It can be administered intravenously or topically (as a cream) to treat skin lesions caused by certain types of cancer.

Mechlorethamine is a potent drug that can have significant side effects, including nausea, vomiting, hair loss, and an increased risk of infection due to suppression of the immune system. It can also cause damage to the heart, lungs, and reproductive system with long-term use. As with all chemotherapy drugs, mechlorethamine should be administered under the close supervision of a healthcare professional.

High-energy radiotherapy, also known as external beam radiation therapy (EBRT), is a type of cancer treatment that uses high-energy radiation beams to destroy cancer cells and shrink tumors. The radiation beams are produced by a machine called a linear accelerator (LINAC) and are directed at the tumor site from outside the body. High-energy radiotherapy can be used to treat many different types of cancer, either alone or in combination with other treatments such as surgery or chemotherapy.

The high-energy radiation beams used in this type of radiotherapy are able to penetrate deep into the body and target large areas, making it an effective treatment for cancers that have spread or are too large to be removed surgically. The dose and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health.

High-energy radiotherapy works by damaging the DNA of cancer cells, which prevents them from dividing and growing. This ultimately leads to the death of the cancer cells. While radiation therapy can also damage normal cells, they are generally better able to repair themselves compared to cancer cells. Therefore, the goal of high-energy radiotherapy is to deliver a high enough dose to destroy the cancer cells while minimizing harm to surrounding healthy tissue.

It's important to note that high-energy radiotherapy requires careful planning and delivery to ensure that the radiation beams are focused on the tumor site and avoid healthy tissues as much as possible. This is typically done using imaging techniques such as CT, MRI, or PET scans to create a treatment plan that maps out the exact location and shape of the tumor. The patient will then undergo a series of treatments, usually scheduled daily over several weeks.

T-cell lymphoma is a type of cancer that affects the T-cells, which are a specific type of white blood cell responsible for immune function. These lymphomas develop from mature T-cells and can be classified into various subtypes based on their clinical and pathological features.

T-cell lymphomas can arise in many different organs, including the lymph nodes, skin, and other soft tissues. They often present with symptoms such as enlarged lymph nodes, fever, night sweats, and weight loss. The diagnosis of T-cell lymphoma typically involves a biopsy of the affected tissue, followed by immunophenotyping and genetic analysis to determine the specific subtype.

Treatment for T-cell lymphomas may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation, depending on the stage and aggressiveness of the disease. The prognosis for T-cell lymphoma varies widely depending on the subtype and individual patient factors.

"T-lymphocyte gene rearrangement" refers to the process that occurs during the development of T-cells (a type of white blood cell) in which the genes that code for their antigen receptors are rearranged to create a unique receptor that can recognize and bind to specific foreign molecules, such as viruses or tumor cells.

The T-cell receptor (TCR) is made up of two chains, alpha and beta, which are composed of variable and constant regions. During gene rearrangement, the variable region genes are rearranged through a process called V(D)J recombination, in which specific segments of DNA are cut and joined together to form a unique combination that encodes for a diverse range of antigen receptors.

This allows T-cells to recognize and respond to a wide variety of foreign molecules, contributing to the adaptive immune response. However, this process can also lead to errors and the generation of T-cells with self-reactive receptors, which can contribute to autoimmune diseases if not properly regulated.

Telangiectasia is a medical term that refers to the dilation and widening of small blood vessels called capillaries, leading to their visibility under the skin or mucous membranes. These dilated vessels often appear as tiny red lines or patterns, measuring less than 1 millimeter in diameter.

Telangiectasias can occur in various parts of the body, such as the face, nose, cheeks, legs, and fingers. They are typically harmless but may cause cosmetic concerns for some individuals. In certain cases, telangiectasias can be a sign of an underlying medical condition, like rosacea, hereditary hemorrhagic telangiectasia (HHT), or liver disease.

It is essential to consult with a healthcare professional if you notice any unusual changes in your skin or mucous membranes, as they can provide appropriate evaluation and treatment recommendations based on the underlying cause of the telangiectasias.

CD30 is a type of protein found on the surface of some cells in the human body, including certain immune cells like T-cells and B-cells. It is also known as Ki-1 antigen. CD30 plays a role in the regulation of the immune response and can be activated during an immune reaction.

CD30 is often used as a marker to identify certain types of cancer, such as Hodgkin lymphoma and anaplastic large cell lymphoma. These cancers are characterized by the presence of cells that express CD30 on their surface.

CD30 antigens can be targeted with immunotherapy, such as monoclonal antibodies, to treat these types of cancer. For example, brentuximab vedotin is a monoclonal antibody that targets CD30 and has been approved for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Lymphatic diseases refer to a group of conditions that affect the lymphatic system, which is an important part of the immune and circulatory systems. The lymphatic system consists of a network of vessels, organs, and tissues that help to transport lymph fluid throughout the body, fight infection, and remove waste products.

Lymphatic diseases can be caused by various factors, including genetics, infections, cancer, and autoimmune disorders. Some common types of lymphatic diseases include:

1. Lymphedema: A condition that causes swelling in the arms or legs due to a blockage or damage in the lymphatic vessels.
2. Lymphoma: A type of cancer that affects the lymphatic system, including Hodgkin's and non-Hodgkin's lymphoma.
3. Infections: Certain bacterial and viral infections can affect the lymphatic system, such as tuberculosis, cat-scratch disease, and HIV/AIDS.
4. Autoimmune disorders: Conditions such as rheumatoid arthritis, lupus, and scleroderma can cause inflammation and damage to the lymphatic system.
5. Congenital abnormalities: Some people are born with abnormalities in their lymphatic system, such as malformations or missing lymph nodes.

Symptoms of lymphatic diseases may vary depending on the specific condition and its severity. Treatment options may include medication, physical therapy, surgery, or radiation therapy. It is important to seek medical attention if you experience symptoms of a lymphatic disease, as early diagnosis and treatment can improve outcomes.

Immunophenotyping is a medical laboratory technique used to identify and classify cells, usually in the context of hematologic (blood) disorders and malignancies (cancers), based on their surface or intracellular expression of various proteins and antigens. This technique utilizes specific antibodies tagged with fluorochromes, which bind to the target antigens on the cell surface or within the cells. The labeled cells are then analyzed using flow cytometry, allowing for the detection and quantification of multiple antigenic markers simultaneously.

Immunophenotyping helps in understanding the distribution of different cell types, their subsets, and activation status, which can be crucial in diagnosing various hematological disorders, immunodeficiencies, and distinguishing between different types of leukemias, lymphomas, and other malignancies. Additionally, it can also be used to monitor the progression of diseases, evaluate the effectiveness of treatments, and detect minimal residual disease (MRD) during follow-up care.

Occlusive dressings are specialized bandages or coverings that form a barrier over the skin, preventing air and moisture from passing through. They are designed to create a moist environment that promotes healing by increasing local blood flow, reducing wound desiccation, and encouraging the growth of new tissue. Occlusive dressings can also help to minimize pain, scarring, and the risk of infection in wounds. These dressings are often used for dry, necrotic, or hard-to-heal wounds, such as pressure ulcers, diabetic foot ulcers, and burns. It is important to monitor the wound closely while using occlusive dressings, as they can sometimes lead to skin irritation or maceration if left in place for too long.

A biopsy is a medical procedure in which a small sample of tissue is taken from the body to be examined under a microscope for the presence of disease. This can help doctors diagnose and monitor various medical conditions, such as cancer, infections, or autoimmune disorders. The type of biopsy performed will depend on the location and nature of the suspected condition. Some common types of biopsies include:

1. Incisional biopsy: In this procedure, a surgeon removes a piece of tissue from an abnormal area using a scalpel or other surgical instrument. This type of biopsy is often used when the lesion is too large to be removed entirely during the initial biopsy.

2. Excisional biopsy: An excisional biopsy involves removing the entire abnormal area, along with a margin of healthy tissue surrounding it. This technique is typically employed for smaller lesions or when cancer is suspected.

3. Needle biopsy: A needle biopsy uses a thin, hollow needle to extract cells or fluid from the body. There are two main types of needle biopsies: fine-needle aspiration (FNA) and core needle biopsy. FNA extracts loose cells, while a core needle biopsy removes a small piece of tissue.

4. Punch biopsy: In a punch biopsy, a round, sharp tool is used to remove a small cylindrical sample of skin tissue. This type of biopsy is often used for evaluating rashes or other skin abnormalities.

5. Shave biopsy: During a shave biopsy, a thin slice of tissue is removed from the surface of the skin using a sharp razor-like instrument. This technique is typically used for superficial lesions or growths on the skin.

After the biopsy sample has been collected, it is sent to a laboratory where a pathologist will examine the tissue under a microscope and provide a diagnosis based on their findings. The results of the biopsy can help guide further treatment decisions and determine the best course of action for managing the patient's condition.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the adaptive immune system's response to infection. They are produced in the bone marrow and mature in the thymus gland. There are several different types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs).

CD4+ helper T-cells assist in activating other immune cells, such as B-lymphocytes and macrophages. They also produce cytokines, which are signaling molecules that help coordinate the immune response. CD8+ cytotoxic T-cells directly kill infected cells by releasing toxic substances. Regulatory T-cells help maintain immune tolerance and prevent autoimmune diseases by suppressing the activity of other immune cells.

T-lymphocytes are important in the immune response to viral infections, cancer, and other diseases. Dysfunction or depletion of T-cells can lead to immunodeficiency and increased susceptibility to infections. On the other hand, an overactive T-cell response can contribute to autoimmune diseases and chronic inflammation.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Lymphoproliferative disorders (LPDs) are a group of diseases characterized by the excessive proliferation of lymphoid cells, which are crucial components of the immune system. These disorders can arise from both B-cells and T-cells, leading to various clinical manifestations ranging from benign to malignant conditions.

LPDs can be broadly classified into reactive and neoplastic categories:

1. Reactive Lymphoproliferative Disorders: These are typically triggered by infections, autoimmune diseases, or immunodeficiency states. They involve an exaggerated response of the immune system leading to the excessive proliferation of lymphoid cells. Examples include:
* Infectious mononucleosis (IM) caused by Epstein-Barr virus (EBV)
* Lymph node enlargement due to various infections or autoimmune disorders
* Post-transplant lymphoproliferative disorder (PTLD), which occurs in the context of immunosuppression following organ transplantation
2. Neoplastic Lymphoproliferative Disorders: These are malignant conditions characterized by uncontrolled growth and accumulation of abnormal lymphoid cells, leading to the formation of tumors. They can be further classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Examples include:
* Hodgkin lymphoma (HL): Classical HL and nodular lymphocyte-predominant HL
* Non-Hodgkin lymphoma (NHL): Various subtypes, such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma

It is important to note that the distinction between reactive and neoplastic LPDs can sometimes be challenging, requiring careful clinical, histopathological, immunophenotypic, and molecular evaluations. Proper diagnosis and classification of LPDs are crucial for determining appropriate treatment strategies and predicting patient outcomes.

... "leukemic mycosis fungoides", "Sézary syndrome preceded by mycosis fungoides", or "secondary mycosis fungoides". Mycosis ... Mycosis fungoides was first described in 1806 by French dermatologist Jean-Louis-Marc Alibert. The name mycosis fungoides is ... Could it be mycosis fungoides?': an approach to diagnosing patch stage mycosis fungoides". Journal of Hematopathology. 8 (4): ... Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell ...
... is a cutaneous condition that usually presents as solitary or ...
Ein Fall von Mycosis fungoides mit Erkrankung von Nerven und mit Lokalisation in den inneren Organe, (with Gustav Scherber) in ... On mycosis fungoides. Paltauf was the author of a highly regarded chapter on agglutination in the Handbuch der pathogenen ... Who Named It Online Library Mycosis fungoides: The pathology of extracutaneous involvement doi:10.1002/1097-0142(197410)34:4. ...
Castoldi G, Cuneo A (May 2005). "Mycosis fungoides/Sezary's syndrome". Atlas of Genetics and Cytogenetics in Oncology and ...
Beigi, Pooya Khan Mohammad (2017). "Variants of Mycosis Fungoides". Clinician's Guide to Mycosis Fungoides. Springer ... Pagetoid reticulosis (also known as "acral mycoses fungoides", "localized epidermotropic reticulosis", "mycosis fungoides ... Could it be mycosis fungoides?': an approach to diagnosing patch stage mycosis fungoides". Journal of Hematopathology. 8 (4): ... Pagetoid reticulosis is a very slow progressive variant of mycosis fungoides and is usually localized unlike the latter. The ...
produced remissions in mycosis fungoides. Joseph Burchenal, at Memorial Sloan-Kettering Cancer Center in New York, with ... "Observations on the use of cancer chemotherapeutic agents in patients with mycosis fungoides". Cancer. 17 (8): 1045-1062. doi: ... Wright, JC; Gumport, SL; Golomb, FM (1960). "Remissions produced with the use of methotrexate in patients with my- cosis ... fungoides". Cancer Chemother Rep. 9: 11-20. PMID 13786791. Wright, JC; Lyons, M; Walker, DG (1964). " ...
A variant of mycosis fungoides. Sur la pathogénie du tabes et des affections parasyphilitiques en général, 1909. Microbiologie ...
... is sometimes considered a late stage of mycosis fungoides with lymphadenopathy. Sézary disease and mycosis ... "FDA approves mogamulizumab-kpkc for mycosis fungoides or Sézary syndrome". U.S. Food and Drug Administration. 2018-08-08. ... The immunohistochemical features are very similar to those presented in mycosis fungoides except for the following differences ... Beigi, Pooya Khan Mohammad (2017). "Diagnosis and Management". Clinician's Guide to Mycosis Fungoides. pp. 13-18. doi:10.1007/ ...
Hodak, E; Amitay-Laish, I (2019-05-01). "Mycosis fungoides: a great imitator". Clinics in Dermatology. 37 (3): 255-267. doi: ... Hypoglycemia as an imitator of a stroke Cancers generally Intravascular large B-cell lymphoma Mycosis fungoides Malignant ...
produced remissions in mycosis fungoides. "methotrexate - definition of methotrexate in English from the Oxford dictionary". ... "Observations on the Use of Cancer Chemotherapeutic Agents in Patients With Mycosis Fungoides". Cancer. 17 (8): 1045-62. doi: ... "Remissions produced with the use of Methotrexate in patients with mycosis fungoides". Cancer Chemotherapy Reports. 9: 11-20. ...
The presentation depends if it is mycosis fungoides or Sézary syndrome, the most common, though not the only types. Among the ... Cutaneous T-cell lymphoma may be divided into the several subtypes.: 727-740 Mycosis fungoides is the most common form of CTCL ... Beigi, Pooya Khan Mohammad (2017). "Treatment". Clinician's Guide to Mycosis Fungoides. Springer International Publishing. pp. ... "Defining early mycosis fungoides" (PDF). Journal of the American Academy of Dermatology. 53 (6): 1053-1063. doi:10.1016/j.jaad. ...
Diagnosis and management of mycosis fungoides. Oncology (Williston Park). 2010 May;24(6):491-501. Lessin SR, Duvic M, Guitart J ... There have been studies demonstrating that topical administration of mechlorethamine has efficacy in mycosis fungoides-type ... gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25-32. McErlane, KM; Wood, RJ; Matsui, F; Lovering, EG (July 1978). " ... mycosis fungoides and the Sézary syndrome)". Annals of Internal Medicine. 121 (8): 592-602. doi:10.7326/0003-4819-121-8- ...
Sézary cells are found in both mycosis fungoides and Sézary disease. It is an unrare form of cancer that originates in the ... Aggregates of these cells in mycosis fungoides are known as a Pautrier's microabscesses. They are a form of T-lymphocytes that ... This leads to the development of non-Hodgkin's lymphoma such as mycosis Fungoides and Sézary disease. The mutated cells are ... Lutzner cells are more predominant in Mycosis Fungoides, but are also found in Sézary Syndrome. Sézary cells are bigger than ...
Mycosis fungoides is the common lymphoma believed to cause PVA, although it may be considered a precursor when the lymphoma is ... It may also be included among a number of similar conditions that are considered as precursors to mycosis fungoides. PVA is ... Additionally, it may be considered a precursor or variant of the lymphomatous skin disorder mycosis fungoides, which is also ... List of cutaneous conditions Howard MS, Smoller BR (Jun 2000). "Mycosis fungoides: classic disease and variant presentations". ...
Safai B, Myskowski P, Dupont B, Pollack M (1983). "Association of HLA-DR5 with mycosis fungoides". J Invest Dermatol. 80 (5): ... mycosis fungoides, polyglandular deficiency syndrome, systemic sclerosis, childhood epilepsy, early-onset alopecia areata, ...
He had also suffered from mycosis fungoides. When Cobb died in 1961, stories written about him mentioned the attempted trade ...
Alibert-Bazin syndrome: Historical name for mycosis fungoides. Named with dermatologist Jean-Louis-Marc Alibert (1768-1837). ...
The epitheliotropic form is typically of T-cell origin and is also called mycosis fungoides. The non-epitheliotropic form is ... March 2006). "Epitheliotropic cutaneous lymphoma (mycosis fungoides) in a dog". Journal of Veterinary Science. 7 (1): 97-99. ... mycosis fungoides, and lupus erythematosus. Signs for lymphoma in other sites depend on the location. Central nervous system ...
List of cutaneous conditions Mycosis fungoides Kikuchi, A.; Naka, W.; Harada, T.; Sakuraoka, K.; Harada, R.; Nishikawa, T. ( ...
2005 Jul;32(7):565-8. Poonawalla T, Chen W, Duvic M (2006). "Mycosis fungoides with tinea pseudoimbricata owing to Trichophyton ... as well as Trichophyton rubrum which can trigger mycosis fungoides. Mixed infections with scabies have been described to ...
... nasal type Enteropathy-associated T-cell lymphoma Hepatosplenic T-cell lymphoma Blastic NK cell lymphoma Mycosis fungoides/ ... "Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience". Radiotherapy ...
... a case of unusual variant of mycosis fungoides". Chin Med J (Engl). 113 (2): 189-92. PMID 11775552. v t e (CS1 maint: DOI ... 735 It is a form of cutaneous T-cell lymphoma and a variant of mycosis fungoides. List of cutaneous conditions "Granulomatous ...
"Clusterin expression correlates with stage and presence of large cells in mycosis fungoides". American Journal of Clinical ...
Mycosis fungoides, which attacks the skin, is the most common form of CTCL. When cancer cells infiltrate and accumulate in the ...
It is expressed in T cell lymphoblastic lymphoma and hypo-pigmented mycosis fungoides. To function, CD8 forms a dimer, ...
... he was the first to describe a patient with mycosis fungoides. The disease was formerly referred to as "Alibert-Bazin syndrome ...
"Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2". Nature Genetics. 47 (9): ...
March 2002). "Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome". The Journal of ...
... or mycosis fungoides. Once in remission, he joked about the coincidence: "Can you imagine that? Cancer with my name on it - ...
She had suffered for some 10 years from a rare disease known as mycosis fungoides. She used Nitschke's device to take her life ...
... "leukemic mycosis fungoides", "Sézary syndrome preceded by mycosis fungoides", or "secondary mycosis fungoides". Mycosis ... Mycosis fungoides was first described in 1806 by French dermatologist Jean-Louis-Marc Alibert. The name mycosis fungoides is ... Could it be mycosis fungoides?: an approach to diagnosing patch stage mycosis fungoides". Journal of Hematopathology. 8 (4): ... Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell ...
Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Explore symptoms, ... medlineplus.gov/genetics/condition/mycosis-fungoides/ Mycosis fungoides. ... Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell ... The tumors in mycosis fungoides, which are composed of cancerous T cells, are raised nodules that are thicker and deeper than ...
Mycosis Fungoides. Mycosis fungoides, or as its known medically Cutaneous T cell lymphoma (CTCL), is not a single disease, but ... Mycosis fungoides evolve over time from malignant white blood cells called T-lymphocytes (T-cells). Their normal function is to ... Causes of Mycosis fungoides. CTCL is sometimes misdiagnosed as the skin discolorations are similar to other less threatening ... There is no definite cause of Mycosis fungoides, but there are theories indicating it may be genetic. What is known is that ...
Mycosis fungoides natural history, complications and prognosis ‎ (← links). *Mycosis fungoides history and symptoms ‎ (← links) ... Mycosis fungoides cost-effectiveness of therapy ‎ (← links). *Mycosis fungoides future or investigational therapies ‎ (← links) ... Pages that link to "Mycosis fungoides risk factors". ← Mycosis fungoides risk factors ... Retrieved from "https://www.wikidoc.org/index.php/Special:WhatLinksHere/Mycosis_fungoides_risk_factors" ...
Black and Hispanic patients had higher inpatient care utilization for mycosis fungoides (MF) - and were admitted at a younger ... Why a mycosis fungoides diagnosis takes so long Black and Hispanic patients who were hospitalized for MF were significantly ... Black and Hispanic patients had higher inpatient care utilization for mycosis fungoides (MF) - and were admitted at a younger ...
This is a recording of a webinar which took place on 2 March 2022. This was webinar was sponsored by Recordati Rare Diseases Group.. ...
Author(s): Obijiofor, Chinemelum; Yin, Emily; Shvartsbeyn, Marianna; Latkowski, Jo-Ann; Ahearn, Ian; Gutierrez, Daniel
... histologically resembling mycosis fungoides (MF). Immunostaining for terminal deoxynucleotidyl transferase (TdT) was positive ... Lymphoblastic Leukemia and the Expression Pattern of Terminal Deoxynucleotidyl Transferase Immunostaining in Mycosis Fungoides ... Lymphoblastic Leukemia and the Expression Pattern of Terminal Deoxynucleotidyl Transferase Immunostaining in Mycosis Fungoides ... cutis presenting with facial nodules and histological epidermotropism with folliculotropism reminiscent of mycosis fungoides ( ...
Immunocytochemical characterisation of cutaneous lymphomas other than mycosis fungoides. Message subject: (Your Name) has ...
The most common diagnosis of cutaneous T-cell lymphoma diagnosis in the practice of dermatology is mycosis fungoides (MF), ... The most common diagnosis of cutaneous T-cell lymphoma diagnosis in the practice of dermatology is mycosis fungoides (MF), ... The most common diagnosis of cutaneous T-cell lymphoma diagnosis in the practice of dermatology is mycosis fungoides (MF), ...
The authors present a rare case of mycosis fungoides with early central nervous system involvement m... ... Mycosis fungoides with early central nervous system involvement.. Filipe PL, Coutinho VS, Canhão P, Gouveia R, Cabeçadas J, ... The authors present a rare case of mycosis fungoides with early central nervous system involvement mimicking an intramedullary ...
... , Cutaneous T-Cell Lymphoma, Sezary Syndrome, Sezary Cell, Sezary Erythroderma. ... Mycosis Fungoides, Cutaneous T-Cell Lymphoma, Sezary Syndrome, Sezary Cell, Sezary Erythroderma ...
Tag: hypopigmented mycosis fungoides. Hypopigmented Mycosis Fungoides in Younger Patients: A Mimicker of Common Hypopigmented ... hypopigmented mycosis fungoides, lymphoma, mycosis fungoides, pediatric lymphomas, phototherapy, prognosis, young patients ...
Mycosis fungoides variants and subtypes (eg, folliculotropic mycosis fungoides, pagetoid reticulosis, granulomatous slack skin ... Mycosis Fungoides/Sezary syndrome. In addition to the NCCN guidelines, the European Organization for Research and Treatment of ... What is the role of participation in a clinical trial in the treatment of mycosis fungoides/Sezary syndrome (MF/SS) non-Hodgkin ... What are the NCCN recommendations for the diagnostic workup of mycosis fungoides/Sezary syndrome (MF/SS) in cutaneous T-cell ...
Mycosis fungoides. Mycosis fungoides is the most common type of cutaneous T-cell lymphoma (44%), which has led some authors to ... Mycosis fungoides. Mycosis fungoides is a malignant lymphoma characterized by the expansion of a clone of CD4+ (or helper) ... Folliculotropic mycosis fungoides. The prognosis associated with folliculotropic mycosis fungoides is worse than that for ... Mycosis fungoides variants and subtypes (eg, folliculotropic mycosis fungoides, pagetoid reticulosis, granulomatous slack skin ...
Mycosis fungoides. (2021).. https://medlineplus.gov/genetics/condition/mycosis-fungoides/. *. Mycosis fungoides (including ... Mycosis fungoides. Share on Pinterest. Mycosis fungoides is the most common form of cutaneous T cell lymphoma, a type of blood ... Mycosis fungoides often shows up as an eczema-like rash in areas that typically get little sun exposure. ... Mycosis fungoides, which is a form of T cell lymphoma, also presents as red, itchy spots on the skin. ...
Dermatopathology reference describes hypopigmented mycosis fungoides histopathology including histologic features and provides ...
Topical synthetic hypericin ointment activated with visible light proved safe and effective in early-stage mycosis fungoides. ... Synthetic Hypericin Photodynamic Therapy Promising for Mycosis Fungoides Estie Mermelstein, MSN, FNP-BC ... Hypericin PDT can be conducted using an at-home lighting unit and may therefore improve access to mycosis fungoides treatment. ... Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): ...
Foss F: Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol 16:421-428, 2004 ... Mycosis Fungoides [17]. *Most common clinical form of cutaneous T-cell lymphomas (CTCL) ...
MYCOSIS FUNGOIDES WITH POIKILODERMA-LIKE SYMPTOMS. Arch Derm Syphilol. 1936;33(2):267-290. doi:10.1001/archderm. ...
Histologically confirmed mycosis fungoides/Sézary syndrome - Stage IA-IVB disease - Must have failed ≥ 1 prior topical ... RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE ... Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome. Not Recruiting ... This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary ...
... ARDIGÓ M;BORRONI, GIOVANNI; ... Background: Hypopigmented mycosis fungoides (MF) is a rare variant of cutaneous T-cell lymphoma, it is more frequent in dark- ... Background: Hypopigmented mycosis fungoides (MF) is a rare variant of cutaneous T-cell lymphoma, it is more frequent in dark- ...
Histology-based classifier to distinguish early mycosis fungoides from atopic dermatitis. Sophie Roenneberg, Stephan Alexander ... Histopathological differentiation of early mycosis fungoides (MF) from benign chronic inflammatory dermatoses remains difficult ...
Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, resulting from the infiltration of malignant T ... Mycosis fungoides (MF) is an indolent type of CTCL and presents as patches, plaques, or tumors 5 . The histopathology of MF in ... Diagnosis of mycosis fungoides: a comparative immunohistochemical study of T-cell markers using a novel anti-CD7 antibody. Appl ... The histological spectrum of early mycosis fungoides: a study of 58 Saudi Arab patients. Oman Med J. 2012; 27(2):134-9. ...
Synonyms: mycosis fungoides of lymph nodes of multiple sites , ... C84.08 is a billable diagnosis code used to specify mycosis ... C84.0 - Mycosis fungoides* C84.00 - Mycosis fungoides, unspecified site* C84.01 - Mycosis fungoides, lymph nodes of head, face ... C84.07 - Mycosis fungoides, spleen* C84.08 - Mycosis fungoides, lymph nodes of multiple sites* C84.09 - Mycosis fungoides, ... Mycosis fungoides, intrathoracic lymph nodes* C84.03 - Mycosis fungoides, intra-abdominal lymph nodes* C84.04 - Mycosis ...
CD30-: Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma. *Pleomorphic T-cell lymphoma ...
Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum Primary Site. Histology. Staging Type. ... If directly assigning SS2000, use the *Mycosis Fungoides/Sezary Disease of Skin, Vulva, Penis, Scrotum* chapter on page 182 of ...
Combining topical imiquimod with local radiotherapy for treatment of mycosis fungoides. *Zhou, Alan (PD/PI) ...
Mycosis fungoides, Advanced. *Dosing Information. *Mycosis fungoides, Advanced: (single agent) 40 to 50 mg/kg IV in divided ... Mycosis fungoides, Advanced. *Dosing Information. *Mycosis fungoides, Advanced: (single agent) 40 to 50 mg/kg IV in divided ... Mycosis fungoides, Advanced: (single agent) oral cyclophosphamide is usually administered at dosages in the range of 1 to 5 mg/ ... Mycosis fungoides, Advanced: (single agent) oral cyclophosphamide is usually administered at dosages in the range of 1 to 5 mg/ ...
Mycosis fungoides, lymph nodes of axilla and upper limb C84.05 Mycosis fungoides, lymph nodes of inguinal region and lower limb ... Mycosis fungoides, intra-abdominal lymph nodes C84.04 ... Mycosis fungoides, spleen C84.08 Mycosis fungoides, lymph nodes ... Mycosis fungoides, lymph nodes of head, face, and neck C84.02 Mycosis fungoides, intrathoracic lymph nodes ...
  • Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell lymphoma. (wikipedia.org)
  • Mycosis fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), but there are many other types of CTCL that have nothing to do with mycosis fungoides and these disorders are treated differently. (wikipedia.org)
  • Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. (medlineplus.gov)
  • Mycosis fungoides , or as its known medically Cutaneous T cell lymphoma (CTCL), is not a single disease, but a group of cancers that attack the lymphatic system. (mightyguide.net)
  • Las Vegas - The most common diagnosis of cutaneous T-cell lymphoma diagnosis in the practice of dermatology is mycosis fungoides (MF), according to Peter W. Heald, M.D., professor of dermatology, Yale School of Medicine, New Haven, Conn., who spoke here at the 27th Annual Fall Clinical Dermatology Conference. (dermatologytimes.com)
  • Mycosis fungoides is the most common form of cutaneous T cell lymphoma , a type of blood cancer that involves infection-fighting white blood cells called T cells. (healthline.com)
  • Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): the FLASH phase 3 randomized clinical trial. (cancertherapyadvisor.com)
  • Background: Hypopigmented mycosis fungoides (MF) is a rare variant of cutaneous T-cell lymphoma, it is more frequent in dark-skinned or Asian patients, particularly children. (unipv.it)
  • Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, resulting from the infiltration of malignant T cells into skin tissues. (iranjd.ir)
  • Cutaneous T-cell lymphoma is a general term from mycosis fungoides or occur spontane- to identify non-Hodgkin's T-cell lymphomas ously, although some authors now consider that primarily affect the skin. (bvsalud.org)
  • subtypes of cutaneous T-cell lymphoma, SS is a malignant neoplasm originating the most common of which are mycosis from T lymphocytes, which involves the fungoides and Sézary syndrome (SS). (bvsalud.org)
  • Immunocytochemical characterisation of cutaneous lymphomas other than mycosis fungoides. (bmj.com)
  • Mycosis fungoides is the most common type, accounting for 60% of CTCLs and almost half of all primary cutaneous lymphomas. (medscape.com)
  • The plaque stage follows the patch stage of mycosis fungoides. (wikipedia.org)
  • The advanced stage of mycosis fungoides is characterized by generalized erythroderma (red rash covering most of the body) with severe pruritus (itching) and scaling. (wikipedia.org)
  • In some affected individuals, patches progress to plaques, the next stage of mycosis fungoides. (medlineplus.gov)
  • Spread to other organs can occur in any stage of mycosis fungoides but is most common in the tumor stage. (medlineplus.gov)
  • The cause of mycosis fungoides is unknown. (medlineplus.gov)
  • There is no definite cause of Mycosis fungoides, but there are theories indicating it may be genetic. (mightyguide.net)
  • Sézary syndrome is, with mycosis fungoides, one of the classic types of CTCL, although it is relatively rare. (medscape.com)
  • In most cases of mycosis fungoides, the diagnosis is reached owing to its clinical features, disease history, and histomorphologic and cytomorphologic findings. (medscape.com)
  • C84.08 is a billable diagnosis code used to specify a medical diagnosis of mycosis fungoides, lymph nodes of multiple sites. (icdlist.com)
  • Gameiro A, Gouveia M, Tellechea Ó, Moreno A. Childhood hypopigmented mycosis fungoides: a commonly delayed diagnosis. (medscape.com)
  • Mycosis fungoides evolve over time from malignant white blood cells called T-lymphocytes (T-cells). (mightyguide.net)
  • Topical synthetic hypericin ointment activated with visible light is a safe and effective photodynamic therapy (PDT) for mycosis fungoides (MF), according to a placebo-controlled, double-blind, phase 3 randomized trial published in JAMA Dermatology . (cancertherapyadvisor.com)
  • We describe an unusual case of T-ALL presenting with folliculocentric, erythematous papules on the face, histologically resembling mycosis fungoides (MF). (karger.com)
  • UVA1 induces T-cell apoptosis, which is one of its proposed mechanisms for improving atopic dermatitis (AD), mycosis fungoides (MF), and localized scleroderma. (skintherapyletter.com)
  • The symptoms of mycosis fungoides are categorized into three clinical stages: the patch stage, the plaque stage, and the tumour stage. (wikipedia.org)
  • Both patch and plaque stages are considered early-stage mycosis fungoides. (wikipedia.org)
  • Mycosis fungoides may progress slowly through several stages, although not all people with the condition progress through all stages. (medlineplus.gov)
  • RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. (stanford.edu)
  • PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed mycosis fungoides/Sezary syndrome. (stanford.edu)
  • If directly assigning SS2000, use the *Mycosis Fungoides/Sezary Disease of Skin, Vulva, Penis, Scrotum* chapter on page 182 of the [SS2000 on-line manual](https://seer.cancer.gov/tools/ssm/ssm2000/SSSM2000-122012.pdf#page=182). (cancer.gov)
  • Lesions - At this point the Mycosis fungoides is entrenched. (mightyguide.net)
  • Histopathological differentiation of early mycosis fungoides (MF) from benign chronic inflammatory dermatoses remains difficult and often impossible, despite the inclusion of all available diagnostic parameters. (dermagnostix.com)
  • The disease mimics many other dermatoses and can be confused with conditions, such as sarcoidosis, discoid lupus erythematosus, mycosis fungoides, and fixed drug eruption. (medscape.com)
  • Mycosis fungoides (MF) and Sézary syndrome (SS) are related conditions, with the same type of cancer t-lymphocytes, that initially grow in different body compartments. (wikipedia.org)
  • Mycosis fungoides is caused by abnormal white blood cells (T-lymphocytes). (wikipedia.org)
  • A group of 243 patients with mycosis fungoides (MF) received treatment with topical applications of dilute acqueous solutions of mechlorethamine and/or systemic chemotherapy over the past 10 years. (johnshopkins.edu)
  • Initial management consisted of en una paciente con topical corticosteroids and oral antihistamines with little clinical response. (bvsalud.org)
  • The tumors in mycosis fungoides, which are composed of cancerous T cells, are raised nodules that are thicker and deeper than plaques. (medlineplus.gov)
  • Certain variations of HLA genes may affect the risk of developing mycosis fungoides or may impact progression of the disorder. (medlineplus.gov)
  • For unknown reasons, mycosis fungoides affects males nearly twice as often as females. (medlineplus.gov)
  • Mycosis fungoides was so named because the tumors can resemble mushrooms, a type of fungus. (medlineplus.gov)
  • Single nucleotide polymorphism in IL-33 or ST2 were described in 9 studies (asthma n = 5, inflammatory bowel disease n = 1, mycosis fungoides n = 1, ankylosing spondylitis n = 1, coronary artery disease n = 1). (cdc.gov)
  • Mycosis fungoides starts so subtly and grows so slowly that it may not be noticed initially. (msdmanuals.com)
  • Itching (pruritus) is the most commonly reported symptom of people experiencing mycosis fungoides with up to 88% of people reporting varying intensities of pruritus that typically worsens as the disease progresses. (wikipedia.org)
  • As with mycosis fungoides, doctors have trouble diagnosing this disease in its early stage even with a skin biopsy. (msdmanuals.com)
  • Mycosis fungoides often shows up as an eczema -like rash in areas that typically get little sun exposure. (healthline.com)
  • Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified. (medlineplus.gov)
  • Poteligeo is used to treat mycosis fungoides or Sézary syndrome in adults. (drugs.com)
  • Black and Hispanic patients had higher inpatient care utilization for mycosis fungoides (MF) - and were admitted at a younger age - compared with White patients, according to an analysis of the 2012-2017 National Inpatient Sample (NIS). (the-hospitalist.org)
  • Hypopigmented mycosis fungoides in Caucasian patients: a clinicopathologic study of 7 cases. (unipv.it)
  • Profile of mycosis fungoides in 43 Saudi patients. (nih.gov)
  • Hypericin PDT can be conducted using an at-home lighting unit and may therefore improve access to mycosis fungoides treatment. (cancertherapyadvisor.com)
  • It is unclear whether these genetic changes play a role in mycosis fungoides, although the tendency to acquire chromosome abnormalities (chromosomal instability) is a feature of many cancers. (medlineplus.gov)
  • Childhood Mycosis fungoides makes up 0.5% to 7.0% of cases. (wikipedia.org)
  • It is not uncommon for Mycosis fungoides to be misdiagnosed, especially when a patient is outside of the age group. (mightyguide.net)